FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2616575055> ?p ?o ?g. }

• W2616575055 abstract "ABSTRACT Oritavancin is a lipoglycopeptide antibiotic that exhibits potent activities against vancomycin-resistant Gram-positive pathogens. Oritavancin differs from vancomycin by a hydrophobic side chain attached to the drug disaccharide, which forms a secondary binding site to enable oritavancin binding to the cross-linked peptidoglycan in the cell wall. The mode of action of secondary binding site was investigated by measuring the changes in the peptidoglycan composition of Staphylococcus aureus grown in the presence of desleucyl-oritavancin at subinhibitory concentration using liquid chromatography-mass spectrometry (LC-MS). Desleucyl-oritavancin is an Edman degradation product of oritavancin that exhibits potent antibacterial activities despite the damaged d -Ala– d -Ala binding site due to its functional secondary binding site. Accurate quantitative peptidoglycan composition analysis based on 83 muropeptide ions determined that cell walls of S. aureus grown in the presence of desleucyl-oritavancin showed a reduction of peptidoglycan cross-linking, increased muropeptides with a tetrapeptide-stem structure, decreased O -acetylation of MurNAc, and increased N -deacetylation of GlcNAc. The changes in peptidoglycan composition suggest that desleucyl-oritavancin targets the peptidoglycan template to induce cell wall disorder and interferes with cell wall maturation. IMPORTANCE Oritavancin is a lipoglycopeptide antibiotic with a secondary binding site that targets the cross-linked peptidoglycan bridge structure in the cell wall. Even after the loss of its primary d -Ala– d -Ala binding site through Edman degradation, desleucyl-oritavancin exhibits potent antimicrobial activities through its still-functioning secondary binding site. In this study, we characterized the mode of action for desleucyl-oritavancin's secondary binding site using LC-MS. Peptidoglycan composition analysis of desleucyl-oritavancin-treated S. aureus was performed by determining the relative abundances of 83 muropeptide ions matched from a precalculated library through integrating extracted ion chromatograms. Our work highlights the use of quantitative peptidoglycan composition analysis by LC-MS to provide insights into the mode of action of glycopeptide antibiotics." @default.
• W2616575055 created "2017-05-26" @default.
• W2616575055 creator A5012617076 @default.
• W2616575055 creator A5042351161 @default.
• W2616575055 creator A5048370915 @default.
• W2616575055 creator A5065906325 @default.
• W2616575055 creator A5082407050 @default.
• W2616575055 date "2017-08-01" @default.
• W2616575055 modified "2023-09-27" @default.
• W2616575055 title "Inhibition of Staphylococcus aureus Cell Wall Biosynthesis by Desleucyl-Oritavancin: a Quantitative Peptidoglycan Composition Analysis by Mass Spectrometry" @default.
• W2616575055 cites W1542897439 @default.
• W2616575055 cites W1963724555 @default.
• W2616575055 cites W1975542955 @default.
• W2616575055 cites W1978477906 @default.
• W2616575055 cites W1996468857 @default.
• W2616575055 cites W2006986627 @default.
• W2616575055 cites W2013076358 @default.
• W2616575055 cites W2013760217 @default.
• W2616575055 cites W2015348105 @default.
• W2616575055 cites W2022858682 @default.
• W2616575055 cites W2029361361 @default.
• W2616575055 cites W2031269216 @default.
• W2616575055 cites W2036862552 @default.
• W2616575055 cites W2040095685 @default.
• W2616575055 cites W2044562813 @default.
• W2616575055 cites W2047279409 @default.
• W2616575055 cites W2063521044 @default.
• W2616575055 cites W2072815562 @default.
• W2616575055 cites W2085089048 @default.
• W2616575055 cites W2086216302 @default.
• W2616575055 cites W2091571555 @default.
• W2616575055 cites W2095457533 @default.
• W2616575055 cites W2102169587 @default.
• W2616575055 cites W2118058022 @default.
• W2616575055 cites W2125934160 @default.
• W2616575055 cites W2139163666 @default.
• W2616575055 cites W2156451166 @default.
• W2616575055 cites W2157885066 @default.
• W2616575055 cites W2162392176 @default.
• W2616575055 cites W2323865636 @default.
• W2616575055 cites W2411256052 @default.
• W2616575055 cites W2567324748 @default.
• W2616575055 cites W2589734778 @default.
• W2616575055 doi "https://doi.org/10.1128/jb.00278-17" @default.
• W2616575055 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5512225" @default.
• W2616575055 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28507244" @default.
• W2616575055 hasPublicationYear "2017" @default.
• W2616575055 type Work @default.
• W2616575055 sameAs 2616575055 @default.
• W2616575055 citedByCount "12" @default.
• W2616575055 countsByYear W26165750552018 @default.
• W2616575055 countsByYear W26165750552019 @default.
• W2616575055 countsByYear W26165750552020 @default.
• W2616575055 countsByYear W26165750552021 @default.
• W2616575055 countsByYear W26165750552022 @default.
• W2616575055 countsByYear W26165750552023 @default.
• W2616575055 crossrefType "journal-article" @default.
• W2616575055 hasAuthorship W2616575055A5012617076 @default.
• W2616575055 hasAuthorship W2616575055A5042351161 @default.
• W2616575055 hasAuthorship W2616575055A5048370915 @default.
• W2616575055 hasAuthorship W2616575055A5065906325 @default.
• W2616575055 hasAuthorship W2616575055A5082407050 @default.
• W2616575055 hasBestOaLocation W26165750551 @default.
• W2616575055 hasConcept C104317684 @default.
• W2616575055 hasConcept C125235067 @default.
• W2616575055 hasConcept C167625842 @default.
• W2616575055 hasConcept C185592680 @default.
• W2616575055 hasConcept C2776634448 @default.
• W2616575055 hasConcept C2779489039 @default.
• W2616575055 hasConcept C523546767 @default.
• W2616575055 hasConcept C54355233 @default.
• W2616575055 hasConcept C55493867 @default.
• W2616575055 hasConcept C86803240 @default.
• W2616575055 hasConcept C87933860 @default.
• W2616575055 hasConcept C89423630 @default.
• W2616575055 hasConceptScore W2616575055C104317684 @default.
• W2616575055 hasConceptScore W2616575055C125235067 @default.
• W2616575055 hasConceptScore W2616575055C167625842 @default.
• W2616575055 hasConceptScore W2616575055C185592680 @default.
• W2616575055 hasConceptScore W2616575055C2776634448 @default.
• W2616575055 hasConceptScore W2616575055C2779489039 @default.
• W2616575055 hasConceptScore W2616575055C523546767 @default.
• W2616575055 hasConceptScore W2616575055C54355233 @default.
• W2616575055 hasConceptScore W2616575055C55493867 @default.
• W2616575055 hasConceptScore W2616575055C86803240 @default.
• W2616575055 hasConceptScore W2616575055C87933860 @default.
• W2616575055 hasConceptScore W2616575055C89423630 @default.
• W2616575055 hasFunder F4320332161 @default.
• W2616575055 hasIssue "15" @default.
• W2616575055 hasLocation W26165750551 @default.
• W2616575055 hasLocation W26165750552 @default.
• W2616575055 hasLocation W26165750553 @default.
• W2616575055 hasLocation W26165750554 @default.
• W2616575055 hasOpenAccess W2616575055 @default.
• W2616575055 hasPrimaryLocation W26165750551 @default.
• W2616575055 hasRelatedWork W1534269471 @default.
• W2616575055 hasRelatedWork W1802305307 @default.
• W2616575055 hasRelatedWork W1896640730 @default.
• W2616575055 hasRelatedWork W1963066284 @default.
• W2616575055 hasRelatedWork W2013798053 @default.

• next